Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

| Takeda is focused on curbing dengue with innovative solutions and public-private partnerships to achieve the WHO’s goal of ...

By implementing the "KnippeRx Cares Technology Ecosystem," KnippeRx has developed a comprehensive end-to-end solution that ...

Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

With Robert F. Kennedy Jr. slated to take the top spot at the U.S. | RFK Jr. has previously expressed a desire to put a stop ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

More than three years into a lawsuit accusing competitor Natera of disparaging its cancer blood test, Guardant Health has ...

While President-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...